On Monday, 10x Genomics reached a noteworthy performance benchmark, with its Relative Strength (RS) Rating jumping into the 80-plus percentile with an improvement to 81, a rise from 77 the day before.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest price moves.
While 10x Genomics is not near a proper buying range right now, see if it goes on to form and break out of a proper chart pattern.
10x Genomics showed 0% EPS growth last quarter, while sales growth came in at 10%. Keep an eye out for the company's next round of numbers on or around Aug. 7.
10x Genomics holds the No. 33 rank among its peers in the Medical-Products industry group. Hinge Health, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
